Michael Secora - 13 Jun 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: RXRX
Reported as of: 13 Jun 2023
Net transaction value: -$333,645
SEC form: 4
Accepted by SEC: 15 Jun 2023, 19:28:58 UTC
Prior SEC filing: 17 May 2023
Next SEC filing: 19 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Golightly, attorney-in-fact

Key filing fact

Michael Secora filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 15 Jun 2023.

Key facts

This page summarizes Michael Secora's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
6 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 15 Jun 2023, 19:28.

Change

Previous filing in this sequence was filed on 17 May 2023.
Current net transaction value: -$333,645.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Options Exercise

Transaction value: $83,250
Shares: +37,500
Change %: +4.7%
Price: $2.22^*
Shares after: 830,413
Date: 13 Jun 2023
Ownership: Direct
Footnotes: F1, F2

RXRX transaction

Class A Common Stock

Sale

Transaction value: $248,308
Shares: -25,000
Change %: -3%
Price: $9.93
Shares after: 805,413
Date: 13 Jun 2023
Ownership: Direct
Footnotes: F1, F3

RXRX transaction

Class A Common Stock

Options Exercise

Transaction value: $83,250
Shares: +37,500
Change %: +4.7%
Price: $2.22^*
Shares after: 842,913
Date: 14 Jun 2023
Ownership: Direct
Footnotes: F1

RXRX transaction

Class A Common Stock

Sale

Transaction value: $251,838
Shares: -25,000
Change %: -3%
Price: $10.07
Shares after: 817,913
Date: 14 Jun 2023
Ownership: Direct
Footnotes: F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RXRX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -37,500
Change %: -4.6%
Price: $0.000000
Shares after: 782,813
Date: 13 Jun 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 37,500
Exercise price: $2.22
Footnotes: F1, F5

RXRX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -37,500
Change %: -4.8%
Price: $0.000000
Shares after: 745,313
Date: 14 Jun 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 37,500
Exercise price: $2.22
Footnotes: F1, F5

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,500,000
Date: 13 Jun 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $2.22
Footnotes: F5

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 116,684
Date: 13 Jun 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $11.14
Footnotes: F6

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,914
Date: 13 Jun 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $11.14

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 404,857
Date: 13 Jun 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $8.55
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023.

Footnote F2

Includes 2,754 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 22, 2023.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $9.59 to $10.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F4

This transaction was executed in multiple trades at prices ranging from $9.63 to $10.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F5

The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

Footnote F6

The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Footnote F7

The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.